[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368867-105":59,"doc-detail-368867-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","hybrid-regulatory-t-cells-camouflaged-architects-of-tumor-immunity","Hybrid regulatory T cells - camouflaged architects of tumor immunity","","Hybrid regulatory T cells (hTregs) are distinguished from conventional Foxp3+ regulatory T cells by stable coexpression of Foxp3 with the transcription factor T-bet. This review surveys hTregs as a CD4+ T-cell subset and emphasizes T-bet+ hTregs, highlighting their IFN-g production, high levels of immune checkpoint molecules (PD-1, CTLA-4, GITR, OX40, TIGIT), and chemokine receptors (CXCR3, CCR5). It describes how IL-10, TGF-b, and IFN-g shape innate and adaptive immunity in the tumor microenvironment, notes recruitment and CD73-driven adenosine-mediated immunosuppression, reviews evidence across cancers, addresses conflicting anti- vs pro-inflammatory roles, and outlines differentiation mechanisms and therapeutic targeting opportunities in cancer immunotherapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hybrid-regulatory-t-cells-camouflaged-architects-of-tumor-immunity/368867/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hybrid-regulatory-t-cells-camouflaged-architects-of-tumor-immunity/368867.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are hybrid regulatory T cells (hTregs) and how do they differ from conventional Foxp3+ Tregs?","Question",{"text":113,"@type":114},"hTregs are a CD4+ T-cell subset defined by coexpression of Foxp3 with effector T-cell transcription factors. The review focuses on how T-bet+ Tregs are distinguished from conventional Foxp3+ Tregs.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What distinctive features do T-bet+ hTregs have in the tumor microenvironment?",{"text":118,"@type":114},"T-bet+ hTregs show IFN-g production and high expression of immune checkpoints such as PD-1 and CTLA-4, along with chemokine receptors CXCR3 and CCR5. They also modulate immunity via secretion of IL-10, TGF-b, and IFN-g and contribute to immunosuppression through CD73-mediated adenosine.",{"name":120,"@type":111,"acceptedAnswer":121},"Why does the review suggest T-bet+ hTregs can have conflicting roles in disease?",{"text":122,"@type":114},"The document notes that some studies associate T-bet+ hTregs with anti-inflammatory behavior through IL-10 and TGF-b and stronger suppression, while other studies report enhanced pro-inflammatory functions in colitis and related pathologies. These contrasting findings motivate further investigation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368867,1790832604,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Review  \nPUBLISHED 17 September 2025 DOI 10.3389/fimmu.2025.1658576  \nOPEN ACCESS  \nEDITED BY  \nSoldevila Gloria,  \nNational Autonomous University of Mexico, Mexico  \nREVIEWED BY  \nRobert Bright,  \nTexas Tech University Health Sciences Center, United States  \nXinyan Wu,  \nChina Agricultural University, China  \n*CORRESPONDENCE  \nEphraim A. Ansa-Addo  \n [Ephraim.ansa-addo@osumc.edu](Ephraim.ansa-addo@osumc.edu)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 02 July 2025  \nACCEPTED 03 September 2025  \nPUBLISHED 17 September 2025  \nCITATION  \nAzimnasab-Sorkhabi P, Soltani-asl M, Kfoury Junior JR and Ansa-Addo EA (2025) Hybrid regulatory T cells: camouﬂaged architects of tumor immunity.  \nFront. Immunol. 16:1658576 .  \ndoi: 10.3389/fimmu.2025.1658576  \nCOPYRIGHT  \n© 2025 Azimnasab-Sorkhabi, Soltani-asl, Kfoury Junior and Ansa-Addo. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nHybrid regulatory T cells: camouﬂaged architects of tumor immunity  \nParviz Azimnasab-Sorkhabi 1,2†, Maryam Soltani-asl 1,2†,  \nJose Roberto Kfoury Junior 3 and Ephraim A. Ansa-Addo 1,2*  \n1 Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, United States, 2 Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, United States, 3 Department of Surgery, School of Veterinary Medicine and Animal Sciences, University of Sao Paulo, Sao Paulo, Brazil  \nDistinct from conventional Foxp3+ regulatory T cells (Tregs), T-bet+ Tregs represent a stable subset of immunosuppressive T cells characterized by coexpression of the transcription factors (TFs) Foxp3 and T-bet. Given that Tregs were also reported to co-express Foxp3 together with effector T cell TFs such as GATA3, or RORgt, we propose the term hybrid Tregs (hTregs) to distinguish between these Tregs that co-express Foxp3 together with effector T cell TFs from conventional Foxp3+ Tregs. Therefore, this review will focus on hTreg cells, aspeciﬁc subset of CD4+ T cells, and discuss the different types of hTregs with particular emphasis on T-bet+ hTregs. T-bet+ hTregs exhibit unique features including IFN-g production, high expression of immune checkpoints (PD-1, CTLA-4, GITR, OX40, TIGIT), and chemokine receptors (CXCR3, CCR5) . Through secretion of IL-10, TGF-b and IFN-g, T-bet+ hTregs modulate both innate and adaptive immune responses within the tumor microenvironment (TME) . Their high expression of CD73 contributes to adenosine-mediated immunosuppression, while CXCR3 and CCR5 facilitate their recruitment to inﬂammatory sites. T-bet+ hTregs were reported to accumulate in multiple human cancers, including lung, ovarian, and colorectal carcinomas. Despite these advancements, the function of hTregs in diseases such as cancer remains poorly understood, and requires further investigations. For instance, some studies suggest T-bet+ hTregs to be antiinﬂammatory due to their production of IL-10, TGF-b, and superior suppressive capacity compared to conventional Tregs. Yet, other studies have reported that Tbet+ hTregs exhibit enhanced proinﬂammatory functions in colitis and other pathologies. We will then highlight current known mechanisms that promote the differentiation and functions of T-bet+ hTregs in cancer. Lastly, we will discuss the advancements and opportunities for therapeutic targeting of T-bet+ hTregs in cancer immunotherapy.  \nKEYWORDS  \nregulatory T cells, hybrid tre g","cbCailMv6pPal6Vs","https://ap.wps.com/l/cbCailMv6pPal6Vs","pdf",2104963,13,"English","# Introduction\n## Tumor microenvironment and immune heterogeneity\n## Regulatory T cells in cancer\n## Hybrid Treg subsets","[{\"question\":\"What are hybrid regulatory T cells (hTregs) and how do they differ from conventional Foxp3+ Tregs?\",\"answer\":\"hTregs are a CD4+ T-cell subset defined by coexpression of Foxp3 with effector T-cell transcription factors. The review focuses on how T-bet+ Tregs are distinguished from conventional Foxp3+ Tregs.\"},{\"question\":\"What distinctive features do T-bet+ hTregs have in the tumor microenvironment?\",\"answer\":\"T-bet+ hTregs show IFN-g production and high expression of immune checkpoints such as PD-1 and CTLA-4, along with chemokine receptors CXCR3 and CCR5. They also modulate immunity via secretion of IL-10, TGF-b, and IFN-g and contribute to immunosuppression through CD73-mediated adenosine.\"},{\"question\":\"Why does the review suggest T-bet+ hTregs can have conflicting roles in disease?\",\"answer\":\"The document notes that some studies associate T-bet+ hTregs with anti-inflammatory behavior through IL-10 and TGF-b and stronger suppression, while other studies report enhanced pro-inflammatory functions in colitis and related pathologies. These contrasting findings motivate further investigation.\"}]","Hybrid regulatory T cells - camouflaged architects of tumor immunity | PDF",1790178992,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5edde0026c0161dd35122060d9371e93.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a36ba324da7dfb41e1fd47d4bacf1d2.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a2ffc7ae0dfebce900d8348402328a6.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a336696b29859235ab95cc142b6e2bfa.webp",980,1385]